(Q64374836)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

6

William M Switzer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Malva I M Hernandez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Fabrizzio S Cezarotto

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jovino D S Ferreira

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Amely B Martins

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Zhiquan Xiang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Hildegund C J Ertl

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Carlos R Zanetti

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Aguinaldo R Pinto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

24 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Construction of adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Replication-defective vector based on a chimpanzee adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Adenoviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.043

10.1016/J.VIROL.2010.07.043

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20797754%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference